A Phase 1 interventional study of Brexpiprazole in Health, sponsored by Otsuka Beijing Research Institute. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-01.
Sponsored by Otsuka Beijing Research Institute (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a single-center, open-label study evaluating the pharmacokinetics, tolerability and safety of single dose oral brexpiprazole tablets in healthy Chinese subjects. A total of 30 healthy adult subjects are to be enrolled into the study. Three dose groups will be set up, with about 10 subjects in each dose group. Subjects will enter 1 mg, 2 mg and 4 mg dose groups in sequence.
A total of 30 healthy adult subjects are to be enrolled into the study. Three dose groups will be set up, with about 10 subjects in each dose group. Subjects will enter 1 mg, 2 mg and 4 mg dose groups in sequence.
After the clinical trial responsible physicians obtain the informed consent forms from subjects, the subjects will be screened 14 days to 1 days prior to taking the study drug (D-14\~D-1).
One day prior to dosing in each group (D-1), the included subjects are hospitalized On the next day (D1), after completed the hospitalization inspection, eligible subjects will be assigned subject numbers to start with the first dose, complete corresponding examination, stay in hospital for observation and be discharged on Day 4 of medication. On days 6, 8, 10, 12 blood samples are collected and safety evaluation will be performed. Telephone follow-up will be performed on day Day31.
Blood samples are collected to determine and evaluate blood concentrations of Brexpiprazole and its main metabolite DM-3411 before dosing, and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours after dosing, with 18 sampling points in total.
Otsuka Beijing Research Institute is the lead sponsor of 36 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dosing group 1, single/oral/with fasting, Brexpiprazole 1.0 mg, 1 tablets
Drug: Brexpiprazole
Dosing group 2, single/oral/with fasting, Brexpiprazole 1.0 mg, 2 tablets
Drug: Brexpiprazole
Dosing group 3, single/oral/with fasting, Brexpiprazole 1.0 mg, 4 tablets
Drug: Brexpiprazole
Brexpiprazole , single/oral/with fasting
Also known as: Brex
The peak concentration (Cmax) after the first administration
The peak concentration (Cmax) of Brexipiprazole and the metabolite DM-3411 after administration
Time frame: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours
The peak time (Tmax) after the first administration
The peak-time of Brexipiprazole and the metabolite DM-3411 on the first day after administration are calculated.
Time frame: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours
Area under the plasma concentration-time curve (AUC0-264h)
The area under the plasma concentration-time curve of Brexipiprazole after administration are calculated.
Time frame: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours
Half time after the first administration
The half time of Brexipiprazole after administration are calculated.
Time frame: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours
Apparent clearance after the first administration
To assess the apparent clearance after administration (CL/F) of Brexipiprazole after the first administration
Time frame: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours
Proportional dose-response relationship between pharmacokinetic parameters Cmax and AUC of OPC-34712
To assess the Proportional dose-response relationship between pharmacokinetic parameters Cmax and AUC of OPC-34712
Time frame: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours
Blood pressure
To seeess blood pressure after administration of brexpiprazole
Time frame: 0, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours
Heart rate
To seeess heart rate after administration of brexpiprazole
Time frame: 0, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours
Body weight
To seeess Body weight after administration of brexpiprazole
Time frame: 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours
12-lead ECG
To seeess 12-lead ECG after administration of brexpiprazole
Time frame: 3, 6, 24, 72, 96, 120, 264 hours
Blood biochemistry
To seeess blood biochemistry after administration of brexpiprazole
Time frame: 24, 96, 264 hours
Blood routine
To seeess blood routine after administration of brexpiprazole
Time frame: 24, 96, 264 hours
urinary routine
To seeess urinary routine after administration of brexpiprazole
Time frame: 24, 96, 264 hours
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2019 to primary completion in May 2020, 13 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Beijing Research Institute →